- Home
- PKE vs ZNTL Comparison
PKE vs ZNTL Comparison
Compare PKE & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PKE
- ZNTL
- Stock Information
- Founded
- PKE 1954
- ZNTL 2014
- Country
- PKE United States
- ZNTL United States
- Employees
- PKE N/A
- ZNTL N/A
- Industry
- PKE Military/Government/Technical
- ZNTL Biotechnology: Pharmaceutical Preparations
- Sector
- PKE Industrials
- ZNTL Health Care
- Exchange
- PKE Nasdaq
- ZNTL Nasdaq
- Market Cap
- PKE 260.2M
- ZNTL 105.8M
- IPO Year
- PKE N/A
- ZNTL 2020
- Fundamental
- Price
- PKE $15.96
- ZNTL $1.36
- Analyst Decision
- PKE
- ZNTL Buy
- Analyst Count
- PKE 0
- ZNTL 7
- Target Price
- PKE N/A
- ZNTL $8.60
- AVG Volume (30 Days)
- PKE 67.0K
- ZNTL 1.4M
- Earning Date
- PKE 07-15-2025
- ZNTL 08-08-2025
- Dividend Yield
- PKE 3.14%
- ZNTL N/A
- EPS Growth
- PKE N/A
- ZNTL N/A
- EPS
- PKE 0.29
- ZNTL N/A
- Revenue
- PKE $62,026,000.00
- ZNTL $26,865,000.00
- Revenue This Year
- PKE N/A
- ZNTL N/A
- Revenue Next Year
- PKE N/A
- ZNTL N/A
- P/E Ratio
- PKE $52.72
- ZNTL N/A
- Revenue Growth
- PKE 10.75
- ZNTL N/A
- 52 Week Low
- PKE $11.96
- ZNTL $1.01
- 52 Week High
- PKE $15.94
- ZNTL $5.44
- Technical
- Relative Strength Index (RSI)
- PKE 72.59
- ZNTL 53.17
- Support Level
- PKE $15.00
- ZNTL $1.29
- Resistance Level
- PKE $15.58
- ZNTL $1.38
- Average True Range (ATR)
- PKE 0.42
- ZNTL 0.10
- MACD
- PKE 0.12
- ZNTL 0.01
- Stochastic Oscillator
- PKE 100.00
- ZNTL 77.97
About PKE Park Aerospace Corp.
Park Aerospace Corp designs develop and manufactures engineered, advanced composite materials and composite structures and assemblies and low-volume tooling for the aerospace markets and prototype tooling for such structures and assemblies. Geographically, the company derives a majority of revenue from North America and also has a presence in a company operates its business in Asia and Europe. It offers advanced composite Prepregs for Aircraft Structures and Interiors, Sigma Strut and Alpha Strut.
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.